Whitepaper: Life Sciences – 409A valuation vs. valuation to raise money

The US Internal Revenue Code has numerous regulations which must be adhered to in order for companies to reach compliance standards. One such regulation, Section 409A of the IRC, governs the complexities of setting strike prices for employee stock options and requires that companies be properly audited before issuing stock options as employee compensation. Often … Continue reading Whitepaper: Life Sciences – 409A valuation vs. valuation to raise money

Read more

Whitepaper: Collaboration of Venture Valuation and Ferring Pharmaceuticals

Switzerland, March 2019: Venture Valuation has been working with Ferring Pharmaceutical supporting the company with external, third-party product/asset valuations of potential in-licensing opportunities. After Ferring had identified a specific opportunity and deemed interesting to move it forward in the internal evaluation process, Venture Valuation was mandated to review the product/opportunity from an external point of … Continue reading Whitepaper: Collaboration of Venture Valuation and Ferring Pharmaceuticals

Read more

Whitepaper: The Rise of Bigger, Earlier M&A Deals for Biotech

Continuing a trend that began in 2017, this year has seen the rise of big investment deals in the biotech sector.  Smaller biotechs are also cashing in as Big Pharma look to fill dwindling pipelines; according to Bloomberg data, biotech acquisitions are expected to be at the highest level for 12 years. Analysing this data from … Continue reading Whitepaper: The Rise of Bigger, Earlier M&A Deals for Biotech

Read more

Whitepaper: Focus on the Antibiotics Market

The antibiotics market is expected to reach USD 57.0 billion by 2024. Rising prevalence of infectious diseases is contributing to the market growth, especially in developing regions such as Asia-Pacific. However, raising capital for companies active in this field has been difficult for the past few years. Thus, Venture Valuation has collected some important facts, … Continue reading Whitepaper: Focus on the Antibiotics Market

Read more